Abstract #0234

Clinical translation of simultaneous metabolic and perfusion imaging with hyperpolarized [1-13C]pyruvate and [13C, 15N2]urea

Hecong Qin^1,2, Shuyu Tang¹, Andrew Riselli¹, Robert A. Bok¹, Romelyn Delos Santos¹, Mark Van Criekinge¹, Jeremy W. Gordon¹, Rahul Aggarwal³, Evelyn Escobar¹, Rui Chen⁴, Chunxin Tracy Zhang⁵, Gregory Goddard⁵, Albert Chen⁴, Galen Reed⁴, Ruscitto M. Daniel⁵, Renuka Sriram¹, James Slater¹, Peder E.Z. Larson^1,2, Daniel B. Vigneron^1,2, and John Kurhanewicz^1,2

¹Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States, ²Graduate Program in Bioengineering, UC Berkeley – UCSF, San Francisco, CA, United States, ³Medicine, University of California, San Francisco, San Francisco, CA, United States, ⁴GE Healthcare, Waukesha, WI, United States, ⁵GE Research, Niskayuna, NY, United States

Altered metabolism and perfusion are implicated in cancer’s underlying pathophysiology. Prior preclinical and clinical studies have shown that metabolic and perfusion imaging could provide a sensitive and specific evaluation of tumor grade and therapeutic response. We aim to develop a dual-agent hyperpolarized ¹³C MR technique for simultaneous metabolic and perfusion imaging in humans. Here, we report the technical developments towards its clinical translation: 1) formulation and co-polarization system of ¹³C pyruvate and urea, 2) imaging probe characterization, 3) safety-related studies, and 4) multi-probe imaging sequence. Upon FDA approval, this work would lead to the first-in-human dual-agent hyperpolarized MR study.

This abstract and the presentation materials are available to members only; a login is required.

Join Here